312 related articles for article (PubMed ID: 35653050)
1. Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.
de Leeuw DC; Ossenkoppele GJ; Janssen JJWM
Curr Oncol Rep; 2022 Nov; 24(11):1387-1400. PubMed ID: 35653050
[TBL] [Abstract][Full Text] [Related]
2. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.
Kantarjian H; Short NJ; DiNardo C; Stein EM; Daver N; Perl AE; Wang ES; Wei A; Tallman M
Lancet Haematol; 2021 Dec; 8(12):e922-e933. PubMed ID: 34687602
[TBL] [Abstract][Full Text] [Related]
4. Updates on targeted therapies for acute myeloid leukaemia.
Kayser S; Levis MJ
Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585
[TBL] [Abstract][Full Text] [Related]
5. [Novel Strategies to Treat Acute Myeloid Leukemia].
Gediga MHE; Middeke JM; Ruhnke L
Dtsch Med Wochenschr; 2023 Apr; 148(8):451-458. PubMed ID: 36990117
[TBL] [Abstract][Full Text] [Related]
6. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
Yamauchi T
Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
[TBL] [Abstract][Full Text] [Related]
7. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Stone RM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
[TBL] [Abstract][Full Text] [Related]
8. The Time Has Come for Targeted Therapies for AML: Lights and Shadows.
Fiorentini A; Capelli D; Saraceni F; Menotti D; Poloni A; Olivieri A
Oncol Ther; 2020 Jun; 8(1):13-32. PubMed ID: 32700072
[TBL] [Abstract][Full Text] [Related]
9. New Treatment Options for Acute Myeloid Leukemia in 2019.
Cerrano M; Itzykson R
Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
[TBL] [Abstract][Full Text] [Related]
10. Management of Acute Myeloid Leukemia (AML) in Older Patients.
Abdallah M; Xie Z; Ready A; Manogna D; Mendler JH; Loh KP
Curr Oncol Rep; 2020 Jul; 22(10):103. PubMed ID: 32725515
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
12. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
13. Ivosidenib in acute myeloid leukemia.
Bruzzese A; Labanca C; Martino EA; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(18):2093-2100. PubMed ID: 37874005
[TBL] [Abstract][Full Text] [Related]
14. Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future.
Choi JH; Shukla M; Abdul-Hay M
Acta Haematol; 2023; 146(6):431-457. PubMed ID: 37459852
[TBL] [Abstract][Full Text] [Related]
15. Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Fimognari F; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(14):1537-1543. PubMed ID: 37392098
[TBL] [Abstract][Full Text] [Related]
16. Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee.
Neuendorff NR; Gagelmann N; Singhal S; Meckstroth S; Thibaud V; Zhao Y; Mir N; Shih YY; Amaro DMC; Roy M; Lombardo J; Gjærde LK; Loh KP
J Geriatr Oncol; 2023 Apr; 14(3):101406. PubMed ID: 36435726
[TBL] [Abstract][Full Text] [Related]
17. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
Wang ES
Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia transformed to a targetable disease.
Saleh K; Khalifeh-Saleh N; Kourie HR
Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy.
Marchetti M; Albertin L; Limberti G; Canicattì M
Expert Opin Pharmacother; 2022 Feb; 23(2):263-272. PubMed ID: 34886738
[TBL] [Abstract][Full Text] [Related]
20. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]